Heterogeneity of Tertiary Lymphoid Structures Predicts Distinct Malignancy and Immune Microenvironment in Prostate Cancer: a Retrospective Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06484127

Enrollment

200

Registered

2024-07-03

Start date

2023-12-01

Completion date

2024-05-30

Last updated

2024-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

The aim of this study was to reveal the predictive value of spatial heterogeneity and maturity difference of tertiary lymphoid structure in pathological sections of prostate cancer patients for clinical features and prognosis. It provides a new idea for the selection of prostate cancer immunotherapy population in the future.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

MALE

Healthy volunteers

Inclusion criteria

1.patients diagnosed with prostate cancer who underwent radical prostatectomy or prostate puncture

Exclusion criteria

1\. incomplete medical records, inadequate follow-up information, and confirmed non-prostatic acinar adenocarcinoma.

Design outcomes

Primary

Measure	Time frame
Correlation between the detection of TLS(tertiary lymphoid structure) and clinical features	1 month

Countries

China

Outcome results